Results 141 to 150 of about 15,669 (253)

Repurposing of Antiplatelet Agent: Cilostazol for the Treatment of Alcohol-Related Liver Disease

Jong Ryul Eun, Seung Up Kim
openalex   +2 more sources

Synergistic Effects of Cilostazol and Probucol on ER Stress‐Induced Hepatic Steatosis via Heme Oxygenase‐1‐Dependent Activation of Mitochondrial Biogenesis [PDF]

, 2016
Yingqing Chen, Indira Pandiri, Yeonsoo Joe, Hyo Jeong Kim, Seul-Ki Kim, Jeongmin Park, Jinhyun Ryu, Gyeong Jae Cho, Jeong Woo Park, Stefan W. Ryter, Hun‐Taeg Chung   +10 more
openalex   +1 more source

Cilostazol increases collateral remodeling and reduces the severity of ischemic stroke. [PDF]

J Cereb Blood Flow Metab
Zhang H, Ding MC, Gong G, Faber JE.
europepmc   +1 more source

ADVERSE DRUG EVENTS ASSOCIATED WITH CILOSTAZOL ADMINISTRATION IN PATIENTS WITH INTERMITTENT CLAUDICATION: A DISPROPORTIONALITY ANALYSIS OF THE FDA ADVERSE EVENT REPORTING SYSTEM (FAERS)

Roaa Naser AlShajrawi, Omar Hamdan, Yousef Al-Mabrouk, Qais Mussa, Ahmad Alsawalmeh   +4 more
openalex   +1 more source

Cilostazol is a promising anti-pseudomonal virulence drug by disruption of quorum sensing [PDF]

Mohammed W. Al-Rabia, Hani Z. Asfour, Nabil A. Alhakamy, Mohammed A. Bazuhair, Tarek S. Ibrahim, Hisham A. Abbas, Basem Mansour, Wael A. H. Hegazy, Noura M. Seleem   +8 more
openalex   +1 more source

Contribuição na prevenção da isquemia cerebral pelo cilostazol, um inibidor da fosfodiesterase III: revisão de literatura [PDF]

, 2008
Marcelo Pereira da Rosa, Gislaine Baroni, Vera Lúcia Portal   +2 more
openalex   +1 more source

Cilostazol Contributes to Risk Reduction of Stroke Recurrence without Mediating a Reduction of Blood Pressure: Results from CSPS.com. [PDF]

J Atheroscler Thromb
Miwa K, Koga M, Omae K, Kamogawa N, Uchiyama S, Hayami S, Shoji M, Hoshino H, Kimura K, Minematsu K, Yamaguchi T, Toyoda K, CSPS.com Trial Investigators.   +12 more
europepmc   +1 more source

Safety and effectiveness of clazosentan in patients after aneurysmal subarachnoid haemorrhage: a second interim report of a post-marketing surveillance in Japan. [PDF]

Neurosurg Rev
Sakata H, Takayama Y, Iwasaki Y, Uchida H, Nishimoto S, Togo O.   +5 more
europepmc   +1 more source

E<b>F</b>fects of Y-6 S<b>U</b>blingual Tablets for Pa<b>T</b>ients with Ac<b>U</b>te Ischemic St<b>R</b>ok<b>E</b> (FUTURE): a phase II, randomised, double-blind, double-dummy, placebo-controlled, parallel trial. [PDF]

Stroke Vasc Neurol
Wang Y, Qiu B, Guan L, Qu H, Pan Y, Huo X, Liu L, Miao Z, Li S, Li Z, Zhao X, Wang Y, Wang L, Liao X, Wang Y.   +14 more
europepmc   +1 more source

Comparison of sympathectomy and cilostazol treatment results in non-revascularized critical leg ischemia

, 2021
Yıldırım GÜLTEKİN, Ali BOLAT, Hüseyin GEMALMAZ   +2 more
openalex   +1 more source